

SEP 10 2004

Seed IP

Facsimile Transmission

September 10, 2004

To: Examiner Michael L. Borin

Fax No: 703-872-9306

Phone No: 571-272-0713

Re: U.S. Patent Application No. 09/519,642

Your Ref:

Seed IP Ref: 210121.478C4

No. of Pages: 4 (including this page)

If you do not receive all pages, please call John T. Oliver at (206) 622-4900 or fax our office.☐ Urgent☐ For Review☒ Please Confirm
Receipt☐ Please Reply
ASAP

Comments:

PLEASE DELIVER IMMEDIATELY TO:EXAMINER: MICHAEL L. BORIN
ART UNIT: 1631

Transmission Information:

Date:

Time:


By:


CONFIDENTIALITY NOTICE:

The information contained in this facsimile message is legally privileged and/or confidential information intended only for the use of the addressee named above. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this facsimile or its content is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile message to us by mail or destroy it without making a copy. Thank you.

TRANSMITTAL FORM <i>(To be used for all correspondence after initial filing)</i>	Application Number	09/519,642
	Filing Date	March 6, 2000
	First Named Inventor	Tongtong Wang
	Art Unit	1631
	Examiner Name	Michael L. Borin
	Attorney Docket No.	210121.478C4

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input checked="" type="checkbox"/> Affidavits/declaration (2 sheets) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (<i>Appeal Notice, Brief, Reply Brief</i>) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (<i>please identify below</i>): _____ _____ _____
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	Carol D. Laherty, Ph.D.	Customer Number 00500
Signature		
Date	September 10, 2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	John T. Oliver	
Signature		Date: September 10, 2004

This collection of information is required by 37 CFR 1.55. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
C:\N\Portals\Manage\UOHNO\514620_1.DOC

**RECEIVED
CENTRAL FAX CENTER****SEP 10 2004
PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Tongtong Wang, et al.
Application No. : 09/519,642
Filed : March 6, 2000
For : **COMPOSITIONS AND METHODS FOR THE THERAPY
AND DIAGNOSIS OF LUNG CANCER**

Examiner : Michael Borin
Art Unit : 1631
Docket No. : 210121.478C4

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF GARY FANGER, PH.D.

The undersigned, Gary Fanger, Ph.D., hereby declares:


1. I am a Scientist at Corixa Corporation, the assignee of the subject application. The following experiments were performed under my supervision.

2. In order to confirm L552S protein expression in various normal lung and lung cancer tissues, immunohistochemistry (IHC) analysis was performed using an affinity purified L552S polyclonal antibody. Specifically, tissue samples were fixed in a formalin solution for 12-24 hrs and embedded in paraffin before being sliced into 8 micron sections. Steam heat induced epitope retrieval (SHIER) in 0.1 M sodium citrate buffer (pH 6.0) was used for optimal staining conditions. Sections were incubated with 10% serum/PBS for 5 minutes. Primary antibody was added to each section for 25 minutes at indicated concentrations followed by a 25 minute incubation with an anti-rabbit biotinylated antibody. Endogenous peroxidase activity was blocked by three-1.5 minute incubations with hydrogen peroxidase. The avidin biotin complex/horse radish peroxidase (ABC/HRP) system was used along with DAB chromogen to visualize L552S expression. Slides were counterstained with hematoxylin to visualize cell nuclei. L552S polypeptide expression was detected in 10/12 lung adenocarcinoma samples, whereas no

Application No. 09/519,642
Declaration of Gary Fanger, Ph.D.
Docket No. 210121.478C4

expression was detected in 13 normal lung samples evaluated. This expression pattern establishes that L552S polypeptides are overexpressed in lung cancer tissue as compared to normal lung tissues and supports the use of the L552S polypeptides as a cancer diagnostic marker.

3. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful, false statements, and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.



Gary Fanger, Ph.D.

9/1/04

Date

286721_1.DOC